REHOVOT, Israel — CollPlant Biotechnologies is positioning its photocurable dermal filler technology to address a growing aesthetic concern: facial volume loss experienced by patients undergoing GLP-1 weight-loss therapies, the company announced Tuesday.
The expanding use of drugs like Wegovy and Ozempic for weight management has led to a noticeable side effect for some patients – a loss of facial fat, skin laxity, and structural deflation, a phenomenon increasingly referred to as weight-loss-related facial volume depletion, according to CollPlant.
CollPlant’s technology utilizes recombinant human collagen (rhCollagen) and is designed to restore volume while likewise providing a regenerative matrix that integrates with surrounding tissue, the company stated. “Rapid weight loss can lead to significant facial volume depletion and skin quality changes,” said Yehiel Tal, Chief Executive Officer of CollPlant. “GLP-1 therapies are creating a modern category of aesthetic indications. CollPlant’s photocurable filler technology was designed for structural tissue restoration – making it particularly relevant for patients experiencing rapid facial volume loss. Our photocurable rhCollagen-based filler platform is designed not only to restore facial contours, but also to provide a scaffold to support tissue regeneration and long-term structural improvement.”
Dr. Jason Bloom, a facial plastic surgeon, noted the increasing prevalence of the issue. “We are seeing a growing number of patients presenting facial volume depletion after significant weight loss, particularly those using newer metabolic therapies. Technologies that go beyond temporary filling and instead support tissue integration and regeneration could represent an important evolution in how we approach these cases,” he said.
Unlike traditional dermal fillers that primarily offer temporary volumization, CollPlant’s approach aims for structural restoration and long-term tissue integration. The filler is activated using a proprietary illumination device, transitioning the gel into a semi-solid implant designed to withstand physical forces while maintaining shape.
CollPlant’s technology is currently in the preclinical stage, with plans to advance towards clinical trials. The company previously announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler in September 2025, according to a company press release. CollPlant is also developing applications targeting age-related volume loss and skin regeneration.
The company has a development and commercialization agreement with AbbVie for dermal and soft tissue fillers, established in 2021.
